GSK acquires 35Pharma

GSK plc has agreed to acquire 35Pharma, a privately held Canadian biopharmaceutical entity, for $950 million. This strategic acquisition is poised to integrate 35Pharma’s investigational drug, HS235, which targets pulmonary hypertension (PH), into GSK’s portfolio. The move underscores GSK's commitment to expanding its pipeline in respiratory and inflammatory diseases, aiming to enhance treatment options for PH, a serious condition with limited current therapies.

Under the terms of the agreement, GSK will take full ownership of 35Pharma's outstanding equity. Central to this acquisition is HS235, an activin signaling inhibitor currently in clinical development and designed to mitigate the risks associated with existing PH therapies. HS235 has undergone phase I clinical trials in healthy volunteers, with further studies planned for pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).

The acquisition aligns with GSK’s strategic imperative to enhance its capabilities in addressing the unmet medical needs of PH patients. Tony Wood, GSK's Chief Scientific Officer, highlighted HS235's potential to become a leading therapy within their respiratory, inflammatory, and immunology (RI&I) portfolio. HS235 promises not only to reduce bleeding risks — a significant drawback of current therapies — but also to provide metabolic benefits such as fat-selective weight loss and improved insulin sensitivity, which are pertinent given the prevalence of obesity in the PH population.

For the broader market, the deal marks a significant step in the competitive landscape of PH treatments, a market projected to grow to $18 billion by 2032. The role of activin signaling inhibitors, like HS235, is projected to become increasingly prominent, potentially capturing a substantial share of the market. The acquisition may catalyze further investment and development in therapies targeting the activin receptor signaling pathway, influencing competitors aiming to establish footholds in this expanding sector.

The agreement is contingent upon standard regulatory approvals and closure conditions, with implications for future research and development milestones to incorporate HS235 into GSK’s treatment arsenal potentially reshaping the approach to managing PH and related metabolic disorders. The integration will likely accelerate GSK’s strategic objectives in advancing therapies for complex chronic diseases affecting multiple organ systems.